SCHEMBL14670848

SCHEMBL14670848

COc1nc(C(C)C)c2ncccc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.38
TOP1 P11387 2/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 2/20 0.34
HSP90AA1 P07900 2/20 0.34
GMNN O75496 1/20 0.34
TP53 P04637 1/20 0.34
MMP2 P08253 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
MMP9 P14780 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16171323 0.78 LMNA (0.42) PRMT5TOP1TLR8TLR7SMN1; SMN2
SCHEMBL14666989 0.78 PRMT5 (0.45) PRMT5TOP1TLR8TLR7SMN1; SMN2
SCHEMBL16541498 0.78 PRMT5 (0.45) PRMT5TOP1PDGFRBPDGFRARAB9A
SCHEMBL14667017 0.77 PRMT5 (0.40) PRMT5TOP1TLR8TLR7SMN1; SMN2
SCHEMBL14667019 0.77 TLR8 (0.52) PRMT5TLR8TLR7LMNA
SCHEMBL14667018 0.77 PRMT5 (0.40) PRMT5TOP1TLR8TLR7RAB9A
SCHEMBL21348050 0.75 POLB (0.48) SMN1; SMN2LMNAMAPTALOX15TSHR
SCHEMBL14666993 0.74 PRMT5 (0.38) PRMT5TOP1TLR8TLR7SMN1; SMN2
SCHEMBL19185218 0.74 PRMT5 (0.38) PRMT5TOP1PDGFRBPDGFRATLR8
SCHEMBL19185191 0.72 APP (0.52) LMNATP53TDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718815-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-08-01 US disclosed
US-20130029982-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, LLC (US) 2013-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029982-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PRMT5 2722/4885TOP1 1788/4885PDGFRB 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.